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ABSTRACT 
 We report the case of a 3-year-old girl, who is the third child of non-
consanguineous parents with short stature, hypertrophic cardiomyopathy and mild 
dysmorphic features; all suggestive of Noonan syndrome. In addition, the patient 
presents with feeding difficulties, deep palmar and plantar creases, sparse hair, and 
delayed psychomotor and language development, all characteristics frequently observed 
in Cardio-facio-cutaneous syndrome. Molecular analysis of the Ras/MAPK pathway 
genes using high resolution melting curve analysis and gene sequencing revealed a de 
novo KRAS amino acid substitution of leucine to tryptophan at codon 53 (p.L53W). This 
substitution was recently described in an Iranian patient with Noonan syndrome. The 
findings described in the present report expand the phenotypic heterogeneity observed 
in RASopathy patients harbouring a KRAS substitution, and advocate for the inclusion of 
genes with low mutational frequency in genetic screening protocols for Noonan 
syndrome and other RASophaties.   
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INTRODUCTION 
 The term “RASopathies” refers to a group of human syndromes caused by 
germline mutations in genes that encode components of the Ras/MAPK signalling 
pathway.1 These syndromes share phenotypic features such as characteristic facies, 
growth retardation, congenital heart defects, developmental delay, learning disabilities, 
cutaneous abnormalities, cryptorchidism and a predisposition to malignancies.2 
RASopathies include Noonan syndrome (NS, MIM 163950), Noonan syndrome with 
multiple lentigines (MIM 115100), Costello syndrome (CS, MIM 218040) and Cardio-
facio-cutaneous syndrome (CFCS, MIM 115150). As the different syndromes exhibit 
overlapping clinical features, sometimes it may be difficult to make a specific diagnosis 
based exclusively on clinical characteristics. The most frequent RASopathy, Noonan 
syndrome, has an incidence of 1 / 1,000 - 2,500 live births,3 but this may be an 
underestimate due to patients with oligosymptomatic forms of the syndrome. Therefore, 
some of these patients may not be recognized during their entire life.2 Germline mutation 
in four genes account for almost 67% of the patients with the clinical diagnosis of NS: 
PTPN11, SOS1, RAF1 and KRAS.4 The small GPTases RAS (HRAS, KRAS, and 
NRAS) are central components of the Ras/MAPK signal transduction pathway. These 
monomeric GTPases act as binary switches, cycling between an active, GTP-bound, 
and an inactive, GDP-bound state. In its active state, RAS interacts with and regulates 
diverse downstream effectors including RAF kinases (B-RAF, RAF1); 
phosphatidylinositol 3-kinase (PI3K), and RALGDS.5  
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Germline KRAS mutations account for approximately 3% of NS cases and 7% of all 
RASopathies including CFCS and a few individuals with a phenotype suggesting CS,6 
which reflects its complex genotype–phenotype correlation. In this study, we document 
the presence of a recently reported KRAS substitution7 in a 3-year-old girl with a 
phenotype suggestive of Noonan syndrome.  
 
CLINICAL REPORT 
 
 The patient is the third child of young non-consanguineous parents with no family 
history of birth defects. Her two older brothers are healthy. During her pregnancy the 
mother had urinary tract infections that required hospitalization. A fetal ultrasound 
performed at 35 weeks gestation showed pulmonary valve stenosis. She was born via 
C- section at 36 weeks gestational age with a birth weight of 3.5 kg (> 90th percentile), 
birth length 47 cm (> 50th percentile) and head circumference of 35.5 cm (> 90th 
percentile). She had transient hypoglycemia. A postnatal echocardiography exhibited 
right ventricle hypertrophy with premature closure of the ductus arteriosus. During her 
first months of life she exhibited apnea, failure to thrive and psychomotor delay.  A 
cardiac catheterization at 2 months of age confirmed pulmonary valve stenosis, which 
was treated with a balloon valvuloplasty resulting in a residual subvalvar pulmonary 
gradient secondary to hypertrophic cardiomyopathy. Since the neonatal period she has 
had feeding difficulties, gastroesophageal reflux with failure to thrive and malnutrition. 
She underwent a gastrostomy with Nissan fundoplication during her first year of life. 
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However, she continued to have poor weight gain and growth velocity, placing her below 
the 5th percentile for chronological age.  
Physical examination at 5 months of age showed a hypotonic, hypoactive and 
undernourished infant that was not tracking  and had strabismus and epicanthal folds. 
She had mild dysmorphic features (Fig. 1, Table 1), slightly over folded helicies, deep 
palmar and plantar creases, soft skin, and sparse hair. She has a hemangioma (2 cm x 
2 cm) in the cranial right vertex that was confirmed with cerebral magnetic resonance. In 
this exam there were no signs of meningo-angiomatosis.  
She has been followed regularly by a multidisciplinary team with early intervention for 
her psychomotor and language delay.  
Her karyotype is 46,XX and no pathogenic variants were found in the PTPN11, SOS1 
and RAF1 genes. However, one missense substitution was documented in the KRAS 
gene. 
 
MATERIALS AND METHODS 
Ethical statement 
 This study, as well as the Informed Consent for DNA extraction, was approved by 
the Ethics Committee of Central Metropolitan Health Service in Santiago, Chile. 
Informed written consents were obtained from patient's parents for the study and 
photographs. 
Point mutation screening 
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 Point mutations in PTPN11 (NM_002834.4), SOS1 (NM_005633.3), KRAS 
(NM_004985.4) and RAF1 (NM_001354689.1) genes were screened by High Resolution 
Melting (HRM) analysis. Briefly, exons frequently associated with RASopathies were 
amplified with specific primers (Supplementary Table S1). The PCR conditions were 1 x 
HOT FirePol® Eva Green® HRM Mix (Solis BioDyne, Estonia) or 1x SensiFAST HRM 
Mix (Bioline, UK), 0.25 - 1 μM each oligonucleotide and 15 ng genomic DNA in a total 
volume of 10 ul. The annealing temperatures for the amplification of the different exons 
are described in Supplementary Table 1. Amplification and melting curve analyses were 
performed in an Eco Real-Time PCR System (Illumina, San Diego, California, USA) and 
those exons with abnormal profiles relative to control samples (at least three) were 
sequenced bi-directionally in an ABI3730XL sequence analyser (Applied Biosystems, 
Foster City, CA, USA).  
KRAS protein modelling 
 The primary structure of KRAS was used as a query sequence to scan against 
the specially curated nr20 (no sequences with >20% mutual sequence identity) protein 
sequence database with HHblits. The search produced an alignment between KRAS 
and homologous proteins, and highlighted conserved residues in the protein family. 
Homologous proteins with known structure were identified by using the Phyre2 
homology-recognition server V 2.0.8 The sequence alignment produced by Phyre2 for 
the highest-scoring hit (PDB ID 1X1R) was analysed visually to highlight the 
conservation of structurally and functionally important amino acid residues. The model of 
KRAS was validated with Coot 9 and through visual inspection by using the 3D graphics 
software Pymol (Schrödinger.com). Single substitutions were created using Coot and 
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validated as mentioned above. These programs revealed that the structure models 
needed no further modifications.  
 
RESULTS 
 Screening of nucleotide changes by high resolution melting curve analysis 
showed an abnormal profile of KRAS exon 3 amplicon from the patient's genomic DNA 
(Supplementary Fig. S1). Sanger DNA sequencing revealed a heterozygous thymine to 
guanine change at position 158 (c.158 T>G). The substitution affects codon 53 (TTG > 
TGG) which leads to a leucine to tryptophan amino acid substitution (p.L53W) (Fig. 2a). 
This substitution was not detected in the patient's parents (maternity and paternity were 
not confirmed) which suggests a de novo event (Fig. 2b). Furthermore, the c.158T>G 
substitution was not detected in 100 healthy controls after allele-specific PCR analysis 
(Supplementary Fig. S2). To date, the substitution p.L53W has not been reported in 
well-established reference databases including ExAC, 1000 Genomes, Ensembl and 
NCBI. 
This substitution is predicted to be either probably damaging (score of 0.996 - sensitivity: 
0.36; specificity: 0.97) or damaging (score 0.00) according to PolyPhen-210 and SIFT, 
respectively. Importantly, the leucine residue at position 53 of KRAS is conserved 
among evolutionary distant species (Fig. 2c) and across RAS family members. A 
structure model of p.L53W was produced to study the plausible consequence of this 
substitution on KRAS protein structure. Although seven rotamers of tryptophan are 
possible, Fig. 2d (up) shows the two most likely rotational isomers of p.W53 as judged 
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by geometry (e.g., chi angle) constrains and the absence of steric clashes with neighbor 
amino acid residues. In both cases the introduction of this bulky hydrophobic amino acid 
in the small cleft formed by the β1, β2 and β3-strands and the α1 and α5-helix is 
predicted to induce local conformational changes to avoid steric clashes among 
residues located in the vicinity.   
DISCUSSION 
 We report a KRAS missense substitution (p.L53W) in a patient with clinical 
features suggestive of Noonan Syndrome, such as characteristic facies (epicanthal 
folds, low-set ears and ptosis), hypertrophic cardiomyopathy and growth retardation. 
The patient also presented with feeding difficulties, deep palmar and plantar creases, 
sparse hair, sparse eyebrows and psychomotor and language delay, all characteristics 
that are common in CFC syndrome patients and unfrequented in NS patients (Table 1). 
The co-occurrence of features of both syndromes in patients with KRAS mutations has 
been described previously11-13 (Table 1) and demonstrated that specific diagnosis based 
exclusively on clinical characteristics is difficult in patients with KRAS pathogenic 
variants. 
Recently, Tafazoli and collaborators7 reported a L53W amino acid residue substitution in 
a patient with a similar phenotype to our patient. Our studies confirm this association 
and show that: i) the p.L53W substitution was not detected in her relatives (de novo) nor 
in 100 healthy controls; ii) the amino acid substitution affects a residue in a position that 
is conserved across the RAS family, including the recently NS associated gene RIT114; 
and iii) that different predictive tools (Poly-Phen and SIFT) classified this substitution as 
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a probably damaging or damaging amino acid residue variant. Taken together, these 
observations, the patient phenotype, and her clinical evolution led to the classification of 
this variant as Probably Pathogenic, according to The American College of Medical 
Genetics and Genomics (ACMG) classification guidelines.15 
Even though an in silico structure model of the KRAS p.L53W mutant has been 
reported,7 the specific amino acid residues or secondary structural elements (α-helix or 
β-strand) whose relative position could be affected by the substitution were not 
described, nor a mechanistic hypothesis proposed to explain the effects of the 
substitution on protein function and/or protein stability. We addressed this gap in 
knowledge and propose a 3D structure model of the pL53W mutant. Our structure model 
suggests that different residues that are located in close proximity to p.L53W can 
undergo important conformational changes to accommodate the bulkier tryptophan 
amino acid residue in the small cleft defined by the β1-β2-β3 strands and the α1 and α5 
helices (magenta residues in Fig. 2d). None of the residues of the small cleft have 
previously been associated with pathogenic substitutions (somatic or germline) or 
analysed in vitro or in vivo to determine the functional consequences of the 
substitutions. Since members of the RAS protein family (eg, KRAS, NRAS, HRAS) 
present a conserved peptide sequence,5 we surveyed for reported mutations affecting 
residues in equivalent positions across the RAS family members HRAS and NRAS. In 
2011 Runtuwene and coworkers16 described a patient with Noonan syndrome with a 
p.I24N substitution in NRAS. The authors showed that the NRAS p.I24N mutant affected 
the GTP bound (active) form, which resulted in much higher MAPK phosphorylation 
activity compared to the wild type protein. The p.I24N mutant would result in a steric 
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repulsion between the α1-helix and the β2-strand. This in turn destabilizes the guanine 
nucleotide binding pocket resulting in an increased GDP to GTP exchange rate due to a 
9:1 ratio of GTP:GDP in the cell. Based on this evidence, the NRAS p.I24N substitution 
was classified as a mild activation mutation. Similar to residue leucine 53, the isoleucine 
at position 24 is conserved between NRAS and KRAS. In the wild type KRAS crystal 
structure the distance between p.I24 and p.L53 is 6.9 Å, whereas the p.L53W 
substitution with the most likely tryptophan rotamer is expected to reduce the distance to 
2.1 Å (Fig. 2d - down). This would produce a strong repulsing force between the side 
chains of the residues that define the α1-helix and the β3-strand, resulting in important 
conformational changes in the vicinity of the GTP-binding pocket. We postulate here that 
the p.L53W substitution is a mild activated KRAS mutant similar to that reported for the 
NRAS p.I24N mutant. To the best of our knowledge, to date only four NS patients with 
the NRAS p.I24N mutation have been described. Those patients share some distinctive 
features with our patient because three of them exhibited hypertrophic cardiomyopathy 
and one had a hemangioma. In the patient we examined, a detailed cardiac study 
showed prenatal right ventricle hypertrophy with premature closure of the ductus 
arteriosus and subsequent postnatal confirmation of  pulmonary valve stenosis and 
hypertrophic cardiomyopathy. In agreement with our findings, Tafazoli and collaborators 
reported pulmonary valve stenosis in the other patient with the KRAS p.L53W 
substitution.7  
In conclusion, this report provides further evidence of one recently reported KRAS 
pathogenic variant with Noonan syndrome, and thus expands the variety of pathogenic 
KRAS variation associated with RASopathies. We also propose a structure-guided 
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mechanistic explanation of the contribution of this substitution in Noonan syndrome. 
Finally, confirmation of the clinical diagnosis in this patient demonstrates the importance 
of the inclusion of genes with low mutational frequency in genetic screening protocols for 
Noonan syndrome and other RASopathies. These findings emphasise the need to 
explore further the potential of modern techniques, such us targeted gene panel 
sequencing, for the diagnosis of syndromes associated with mutations in genes of the 
Ras/MAPKpathway. 
 
NOTE 
Written informed consent was obtained from the patient’s mother for publication of this 
case report and accompanying images. 
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FIGURE LEGENDS 
Fig. 1: Facial photographs of patient at five months (a) and three years (b) of age 
showing hypertelorism, epicanthal folds, mild ptosis, sparse hair and low set ears.  
Fig. 2: KRAS missense mutations. a) Sequence analyses of the KRAS exon 3 shows a 
heterozygous base substitution of thymine c.158 by guanine in the patient. A wild type 
reference sequence is shown. The black line under the nucleotides sequence highlights 
the codon 53 (NM_004985.4). b) Pedigree chart of the patient, where genotype for 
nucleotide c.158 (T/T or T/G) is shown for each family member, as well as the 
corresponding chromatogram. c) Amino acid sequence alignment of the human KRAS 
strand 3 (β3, amino acid residues 51 to 60) with the orthologues from different species, 
where the amino acid residue leucine 53 is indicated with arrows. Secondary structure 
organization diagram of KRAS showing the position of β3, the substitution p.L53W, and 
two NS associated residues substitutions that are close to p.L53. Both switch regions 
(SW I and SW II) and the hypervariable region (HVR) are also shown. d) [up] Three-
dimensional structure of the KRAS protein with two possible rotamers of p.W53 (purple 
and green side chains). Residues affected by the p.L53W substitution are show in 
magenta. [down] Atom distances between p.I24 and p.L53 (left) or p.W53 (right) side 
chains. 
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Result of the HRM analysis for KRAS exon 3 in patient, reference samples (wild type - WT) and controls 
with known nucleotide changes (rs115908336 T/G). 
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Supplementary Fig. S2 
 
Allele-specific PCR 
Confirmation of a c.156 T>G substitution and analysis of healthy controls was performed by 
allele-specific PCR method. Briefly,  genomic DNA (37,5 ng) was incubated with the forward 
primers KRAS-3_156T (5' GGAGAAACCTGTCTCTT 3') or KRAS-3_156G (5' 
GGAGAAACCTGTCTCTG 3') and the reverse primer KRAS-3R 
(CCTACCTCATAAACATTATTTAA 3'); 1X Green GoTaq® Flexi Buffer; 2 mM MgCl2; 0.2 mM 
dNTPs and 1 unit of GoTaq® G2 Flexi DNA Polymerase; in a final volume of 15 μl. Amplification 
was performed in a T960 thermocycler (Hangzhou Jingle Scientific Instrument, China) with the 
following thermal cycles: 2 minutes at 95°C; 30 cycles of 30 seconds at 95°C, 30 seconds at 
55°C and 30 seconds at 72°C; followed by a final extension of 5 minutes at 72°C. The PCR 
products were separated on a 2% agarose gel and stained with SYBR® Safe DNA Gel Stained 
(Invitrogen, OR, USA). 
 
 
 
 
 
 
 
 
Result of allele-specific PCR for c.156 T>G substitution of KRAS exon 3 in reference sample (wild type - 
WT); Patient and non template control (NTC). Black arrowhead indicates 300 bp standard (MW) and white 
arrowhead depicts the ~ 270 bp amplicon. 
     MW                   WT                   Patient                NTC 
                       T            G               T            G             T           G             Allele 
Genotype                          T / T                         T / G                               
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Supplementary Table S1: Primers used for exon amplification 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genes Exons Primers sequence (5' > 3') Annealing T° (°C) Amplicon size (nt.) 
PTPN11 
2# 
F: GTA GTG CTG ACA GTG TC TTG T 
R: CAG CAA GCT ATC CAA GCA TGG T 
60 258 
3# 
F: CGA CGT GGA AGA TGA GAT CTG A 
CAG TCA CAA GCC TTT GGA GTC AG 
TD_ 70 - 62 384 
4# 
F: ACA ACA TGA ACC CAT AGT AGA GC 
R: CAG AAA AAT CAC CCA AAG GTA 
58 350 
7# 
F: GAA CAT TTC CTA GGA TGA ATT CC 
R: GGT ACA GAG GTG CTA GGA ATC A 
60 271 
8# 
F: GAC ATC AGG CAG TGT TCA CGT TAC 
R: CCT TAA AGT TAC TTT CAG GAC ATG 
60 350 
12# 
F: GCT CCA AAG AGT AGA CAT TGT TTC 
R: GAC TGT TTT CGT GAG CAC TTT C 
60 250 
13# 
F: TCA TCC TGG CTC TGC AGT TTC TCT 
R: CGT ATC CAA GAG GCC TAG CAAG 
66 262 
SOS1 
6# 
F: AAA TGA CTT ATT GGC TCA AAA T 
R: TTA GTA TCT ATG ACT TTA GCT GGA A 
TD_ 60 - 52 324 
7# 
F: TTG TGC TCG CAT AGT CGT G 
R: GGA GAC AGT GGT AAA CAG GG 
65 357 
8# 
F: CGA CCT GGT TTT CAT GAT 
R: ACT AAT GTG CAG GGT ACT CA 
60 300 
10.1*# 
F: AAT CTA CTT TTA CAC TTT CCC 
R: TAA TTT GTA CCT TTC GCA TA 
54 388 
10.2*# 
F: TTG GAC AGT GTT GTA ATG AAT TT 
R: CTC ATC TGC TCC TCT TTC TC 
54 394 
10.3*# 
F: TAG TGT TAT ATT TTC TGC CAA G 
R: AGT TTC TTT TCT ATT TTA GGC AC 
54 390 
11# 
F: TTC TAC TTG GCA AAA CAT T 
ATT TCT GAA AAG GAT CTT AGC 
TD_ 60 - 52 285 
12# 
F: AAA CGT TTG TGG TTT TCT ATT TG 
R: TTT ATT GTC ACC CCT CTC 
54 300 
16# 
F: AAA TTC TTT AAG CTA TAA CTT TA 
R: ACC AAT TCA TTA CAA AAC TTA G 
TD_ 60 - 52 386 
RAF1 
7# 
F: GCC CTT AAG CAT CTT ACT TAG TC 
R: TGA AAC CCA AAA CTC TGA AAT AA 
60 330 
12# 
F: GGG AAA GCA CAG TAG ACC TC 
R: ACAGAATCGCTTAATGGACTAGA 
56 348 
14$ 
F: GTG TTA TAA AGA ACT TTG GGA TA 
R: CTA GGG GTC ATG TGG ATT 
54 317 
17# 
F: AGG GTA CAT CCT GTG TCT TTG AG 
R: AGG GAG CAG AAA AGT GGT G 
60 275 
KRAS 
2$ 
F: ATT AAC CTT ATG TGT GAC ATG TT 
R: CCT TTA TCT GTA TCA AAG AAT G 
54 242 
3$ 
F: ATA ACA CCT TTT TTG AAG TAA A 
R: CCT ACC TCA TAA ACA TTA TTT AA 
TD_ 56 - 48 369 
6$ 
F: GAA GAG AAA CAT AAA GAA TCC 
R: GTG TAA TGT ACA AAA ATT ACC AC 54 293 
F: forward; R: reverse; nt.: nucleotides; TD: touchdown technique, * exon 10 is analyzed in three fragments, 
# HOT FirePol® Eva Green® HRM Mix, $ SensiFAST HRM Mix. 
